Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102498 | 0.86 | KDM1A (0.37) | PTGS2PTGS1FAAHKDM1AFGFR2 | |
| SCHEMBL16855842 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1FAAHKDM1AALOX5 | |
| SCHEMBL20111651 | 0.85 | FGFR2 (0.38) | PTGS2PTGS1KDM1AALOX5GABRA1 | |
| SCHEMBL16855917 | 0.80 | FGFR2 (0.46) | PTGS2PTGS1FAAHKDM1AFGFR2 | |
| SCHEMBL1311903 | 0.78 | GABRA1 (0.43) | FAAHALOX5GABRA1GABRB2FGFR2 | |
| SCHEMBL16856038 | 0.76 | PTGS2 (0.47) | PTGS2PTGS1KDM1ANAAA | |
| SCHEMBL16852379 | 0.75 | FAAH (0.41) | PTGS2PTGS1FAAHKDM1AFGFR2 | |
| SCHEMBL16855843 | 0.75 | ESR1 (0.45) | PTGS2ALOX5GABRA1GABRB2ESR1 | |
| SCHEMBL16852378 | 0.75 | NAAA (0.43) | PTGS2PTGS1FAAHKDM1AGABRA1 | |
| SCHEMBL16572512 | 0.75 | FAAH (0.39) | PTGS2PTGS1FAAHKDM1AFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | PTGS2 4062/4885PTGS1 3924/4885FAAH 1090/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | PTGS2 4062/4885PTGS1 3924/4885FAAH 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.